NCT01693419 - S-1, Gemcitabine and Erlotinib for Advanced Pancreatic Cancer | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

August 31, 2011

Primary Completion Date

December 31, 2016

Study Completion Date

December 31, 2016

Conditions

Pancreas Neoplasms

Interventions

DRUG

GES (Gemcitabine, Erlotinib, S-1)

"Treatment will be delivered as a 3-week cycle.~1. Gemcitabine 1000 mg/m² IV on day 1, 8~2. Erlotinib 100 mg/day PO on day 1~3. S-1 60 mg/m²/day PO on day 1-14"

Trial Locations (1)

Unknown

Hallym University Medical Center, Anyang